Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic
  • Search Hotels in Walnut Creek Guide

  • ROOMS:

Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)

For decades leading up to the 21st century, people referred to it as the period that would usher in an unrivaled period of technological transformation. And they were right. Smart devices, DNA vaccines, digital technology, and electric vehicles are no longer futuristic; they're mainstream. And it happened so quickly that people hardly had the time to embrace the speed at which it happened.

Now, believe it or not, people are discussing what the 22nd century will bring. Indeed, with roughly 80 years to go, imagining the changes is almost limitless. Still, many expect the most significant advancements to come to the medical sector, where today's companies are already developing 22nd-century treatment solutions. Defence Therapeutics (OTC Pink: DTCFF) is one of those companies.

And even though people can shrug off amazing and innovative technology by setting expectations at lofty heights, recognizing what Defence is doing today is invariably impressive. Better still, combining technology with strategy, they are developing enhanced treatment solutions for cancer and infectious diseases on both the micro and macro-level. In other words, they are working to usher in a new era of treatment and methods that can change the therapeutic landscape.

Don't be misled, though. While its technology can be described as 22nd-century innovation, Defence plans to deliver its treatment-changing therapeutics to the market in the coming quarters.

Advancing Novel Vaccine Technology

In fact, only last week, Defence announced its development of a "non-injectable" second-generation COVID vaccine, AccuVAC-IN002, for intranasal delivery. It's a timely contribution, coming after vaccination against SARS2-COVID becomes less successful in slowing the viral spread as new and more infectious strains challenge the strength of current vaccines.

And that's happening for a couple of reasons. First, detected mutations can escape generated humoral responses. And, second, researchers found that people infected with the Delta strain carry 1260 times more virus in their nasal cavity than the original version of the coronavirus.Therein lay the challenge, and the opportunity, that Defence intends to exploit.

Remember, even the best vaccines that aren't administered in the right way can be ineffective. That's proving true with COVID, as current vaccination strategies don't ensure protection from airborne transmission at mucosal sites, which represent the initial site of infection. Thus, despite the well-placed intention, vaccinated individuals can still be infected and possibly develop life-threatening symptoms. Defence Therapeutics thinks it can do better.

And results speak for themselves. Its new AccuVAC-IN002 formulation is inducing both IgA and IgG antibody responses both systemically and at mucosal sites. That action ensures a transmission-blocking effect that may do more than halt initial infection; it can also facilitate close to a 100% blockade in viral shedding. Better still, its AccuVAC-IN002 formulation can be further developed to become a "universal" vaccine capable of targeting 4-8 strains simultaneously, ultimately providing effective protection against known variants and expected future emerging strains.

Even better in the near term, its AccuVAC-IN002 vaccine is scalable. And with the progression of the SARS-COVID virus suggesting that new influenza-like seasonal virus could require a new vaccine every 6-12 months, Defence is better positioned than many to fight airborne disease and other emerging pathogens through its vaccine development program.

Hence, headlines on its developments can serve as both milestones and catalysts. Better yet, with its stock thinly traded, good news could send its shares sharply higher. It's already touching its 52-week high and currently trading higher by more than 156% since May of this year.

However, with potential near-term catalysts in sight, the trend can remain decidedly bullish.Its pipeline further supports that presumption.

Firepower From Impressive Pipeline

In addition to its innovative vaccine development program targeting infectious disease, Defence is advancing its DC vaccine program against cancer with its AccuVAC-D001 treatment candidate.

While there isn't much data published yet, the takeaway is that its scalable Accum technology platform puts the company in a position to efficiently develop universal therapeutic vaccines for cancer and infectious diseases.

And as the markets and analysts come to better understand the power and potential of its technology, Defence's current $6.40 share price could be met with enthusiastic interest.

And that would be well-deserved. Its innovative pathways toward success focus on drug development research's intricacies, utilizing cell nucleus drug delivery technology as a priority. It's a novel approach. Moreover, its solutions intend to fill a treatment gap currently left exposed by Big Pharma. Better yet, by owning its technology, Defence doesn't need to go it alone; they are well-positioned to license its technology to take advantage of global treatment opportunities. That strategy could be the most efficient and effective way to maximize its assets.

It can also accelerate the potential of its platform. And with Big Pharma tending to acquire instead of developing new assets, Defence may very well attract interest from potential partners and collaborators wanting a piece of its current and future vaccine candidates. These deals happen nearly every day in the sector. In Defence's case, there's plenty for potential partners to like.

First To Market Potential

Foremost, they are the first known company to develop a combined technology using precision and efficient cell nucleus for targeted drug delivery. Even better, this proprietary and scalable technology could already rival other best-in-class programs targeting disease and infection. And by owning its assets, value can be tapped into if needed.

Its team is strong as well. Beyond its technology, Defence combines the power of having access to world-class and award-winning researchers, University level facilities, a leading global health care system, and a sophisticated investor community to support its value proposition. Bringing that all together is an aggressive, accelerated growth model with two innovative and proprietary pathways to get its drug candidates to market. Both have substantial intrinsic and inherent near and long-term value.

Its ACCUM™ Technology is the delivery platform making its vaccines accessible across multiple channels. Better still, it's a scalable delivery platform with an enormous multiplier effect that diversifies its market opportunities. Most importantly, its ACCUM™ Technology is a proprietary platform technology with proven enhanced drug delivery methods and has inherent applications to target oncology, vaccine development, and nanotechnologies.

And, as noted, Defence has full ownership of its assets and IP and is already engaging in collaborations with pharma & biotech companies. Notably, the ACCUM™ technology has already helped develop its SARS2- COVID-19 and cancer vaccine. Hence, it's a platform in motion.

The other part of its scalable model comes through its Vaccine Development program. There, the company engages with its team and collaborators to develop virus formulations and create new products. Assets on this side of the pipeline are also 100% owned. As mentioned earlier, the priority research happening now focuses on developing effective and novel vaccines for COVID-19 and cancers. Accelerating this part of its business is a research contract with the University of Montreal.

On Target To Deliver Next-Level Vaccine Innovations

What's the combined goal? To develop next-level innovations for enhanced patient treatment options. Moreover, to overcome the current limitations of marketed treatments by staying focused on existing and longer-term mutations of these conditions. The excellent news is that Defence's data shows that a viable and scalable biopharmaceutical solution is within reach to compensate for what are becoming ineffective long-term treatments.

Moreover, they are showing an ability to provide effective therapeutic value without radiation and chemotherapy, which kill both cancer and healthy cells simultaneously. Included in that effort is a workaround from Nuclear-targeted biopharmaceuticals, which struggle with molecular obstacles limiting the potential for those discoveries to become a therapeutic standard for human diseases.

But, with research, those programs may get better. After all, the intent is excellent. However, Defence is already on point. And they believe its ACCUM™ Technology can overcome the challenges that antibody-drug conjugates (ADC's) present. Already, its technology shows that its drug delivery abilities are 10x over current ADC's, making its ACCUM™ platform an ideal contributor for current and future drug treatments. Better still, by having applications that serve many indications, Defence is introducing ACCUM™ as a global treatment solution. And it can be a treatment game-changer in many targeted conditions.

The power of the treatment proposition comes from combining its two programs. And Defence is confident that the pairing can become the therapeutic standard for human diseases. Moreover, they hit on the most important consideration as well. The platform shows that it can work.

ACCUM™Technology has shown an ability to deliver better results compared to competitors in the market. That's primarily because ACCUM™ Technology takes its therapeutic firepower directly to the diseased cells.

Acceleration Through Collaboration

And they are building upon impressive results by partnering with the academic laboratory and resources available through Dr. Moutih Rafei at the University of Montreal (Canada). There, the focus is on infectious disease and virus vaccine development utilizing the ACCUM™ platform for targeted drug delivery and effective treatments.

Already, data shows that by using ACCUM™, more potent drug delivery is prominent and that vaccine solutions can be applied to any virus or infectious disease. Notably, the resources to expedite trials are substantial, utilizing state-of-the-art facilities at the University of Montreal's ample laboratory space, accommodating 12 highly qualified personnel and a wide range of equipment.

And the team is finding that within its scalable vaccine development universe, its results are not limited to a single indication. While COVID and cancer are priorities, a near-limitless number of other treatment targets could be in play. Keep this in mind, too. Defence is in a valuable sector.

In October of last year, Gilead (NASDAQ: GILD) acquired Immunomedics for $21 billion. In sympathy. Valuations at BioNTech (Nasdaq: BNTX) and Mersana Therapeutics (Nasdaq: MRSN) ran higher as well. Of course, with Defence shares higher by more than 156% YTD, they weren't left out either. Still, its pipeline is deserving of more value. And the remainder of this year and next could be transformative on the shareholder value side as well.

Helping to drive that value, Defence is demonstrating that ACCUM™ technology can enhance the therapeutic value of three already approved ADC's. This fiscal year, the company is expected to provide data showing improved tumor killing by applying ACCUM™ ADCs to murine models of human cancers and determine the pharmacokinetics (PK), ADC distribution, and anti-tumor killing efficacy.

On the vaccine development side, the company is advancing proactive animal testing of a Prophylactic vaccination compared with Reactive Testing, a therapeutic vaccination to treat existing disease. Following that, review and publication of results. And with two compounds ready, supported by positive data generated in Q1 and Q2 of 2021, updates could be imminent.

Value-Opportunity From Powerful Pipeline In-Play

Thus, there's value on the table from an investor's perspective. And with a small float and tight liquidity, stock price moves could be fueled by headlines. The best news there is that Defence Therapeutics has consistently delivered positive news to the markets. Hence, with precedent in place, the next one could be a catalyst to move the stock well beyond current levels.

Indeed, there are a lot of respectable research companies in play. But they aren't apples-to-apples comparisons. The best consideration is finding the companies focused on innovation, have owned assets, and show a proven track record of progress and success. Investing in a company with all that can be the difference between near and long-term gains and drawn-out, expensive clinical failure. With Defence Therapeutics having the ingredients, they present a compelling value opportunity.

Keep in mind, though, with updates potentially imminent, the value today might not be there tomorrow. Thus, its value-proposition at these levels is both compelling and timely.


Disclaimers: STM, LLC. is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: STM, LLC.
Contact Person: Michael Thomas
Phone: 973-820-3748
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.